Innoviva (INVA) Retained Earnings (2010 - 2026)
Innoviva posted quarterly Retained Earnings of $456.0 million for Q1 2026, up 1042.44% year-on-year from $39.9 million in Q1 2025, and up 69.27% on a QoQ basis from $269.4 million in Q4 2025.
Innoviva (INVA) has 17 years of Retained Earnings data on file, last reported at $456.0 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 1042.44% year-over-year to $456.0 million; the trailing twelve-month figure through Mar 2026 stood at $456.0 million (up 1042.44% YoY), and the FY2025 full-year result was $269.4 million, up 15089.87% from the prior year.
- Retained Earnings for Q1 2026 stood at $456.0 million, up from $269.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $456.0 million in Q1 2026 and bottomed at -$204.9 million in Q4 2022.
- The 5-year median for Retained Earnings is -$23.3 million (2024), against an average of -$2.0 million.
- Peak annual rise in Retained Earnings reached 15089.87% in 2025, while the deepest fall reached 526.53% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$204.9 million in 2022, then jumped by 87.71% to -$25.2 million in 2023, then jumped by 92.87% to -$1.8 million in 2024, then jumped by 15089.87% to $269.4 million in 2025, then jumped by 69.27% to $456.0 million in 2026.
- The last three Retained Earnings figures came in at $456.0 million (Q1 2026), $269.4 million (Q4 2025), and $105.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 455.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455.96 Mn |
| Dec 31, 2025 | 269.37 Mn |
| Sep 30, 2025 | 105.22 Mn |
| Jun 30, 2025 | 15.31 Mn |
| Mar 31, 2025 | -48.38 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | -22.13 Mn |
| Jun 30, 2024 | -23.34 Mn |
| Mar 31, 2024 | 11.34 Mn |
| Dec 31, 2023 | -25.19 Mn |
| Sep 30, 2023 | -86.72 Mn |
| Jun 30, 2023 | -168.77 Mn |
| Mar 31, 2023 | -170.05 Mn |
| Dec 31, 2022 | -204.91 Mn |
| Sep 30, 2022 | -136.60 Mn |
| Dec 31, 2021 | -456.15 Mn |
| Sep 30, 2021 | -466.49 Mn |
| Jun 30, 2021 | -538.93 Mn |
| Mar 31, 2021 | -627.88 Mn |
| Dec 31, 2020 | -722.00 Mn |
| Jun 30, 2020 | -804.12 Mn |
| Mar 31, 2020 | 33,000.00 |
| Dec 31, 2019 | -946.40 Mn |
| Sep 30, 2019 | -992.35 Mn |
| Jun 30, 2019 | -1.03 Bn |
| Mar 31, 2019 | -1.07 Bn |
| Dec 31, 2018 | -1.10 Bn |
| Sep 30, 2018 | -3,000.00 |
| Jun 30, 2018 | -10,000.00 |
| Mar 31, 2018 | -22,000.00 |
| Dec 31, 2017 | -1.50 Bn |
| Sep 30, 2017 | -3,000.00 |
| Mar 31, 2017 | -1.62 Bn |
| Dec 31, 2016 | 1,000.00 |
| Sep 30, 2016 | -1.66 Bn |
| Jun 30, 2016 | -1.67 Bn |
| Mar 31, 2016 | -1.69 Bn |
| Dec 31, 2015 | -2,000.00 |
| Sep 30, 2015 | 11,000.00 |
| Jun 30, 2015 | -1.69 Bn |
| Mar 31, 2015 | -12,000.00 |
| Dec 31, 2014 | -1.67 Bn |
| Sep 30, 2014 | -197,000.00 |
| Jun 30, 2014 | -1.64 Bn |
| Mar 31, 2014 | 171,000.00 |
| Dec 31, 2013 | 162,000.00 |
| Sep 30, 2013 | 202,000.00 |
| Jun 30, 2013 | -1.41 Bn |
| Mar 31, 2013 | 92,000.00 |
| Dec 31, 2012 | -1.33 Bn |
| Sep 30, 2012 | 116,000.00 |
| Jun 30, 2012 | -109,000.00 |
| Mar 31, 2012 | -9,000.00 |
| Dec 31, 2011 | 16,000.00 |
| Sep 30, 2011 | 16,000.00 |
| Jun 30, 2011 | -1.25 Bn |
| Dec 31, 2010 | 33,000.00 |